Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
about
Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus.Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
P2860
Q34390763-908BC009-6881-40D2-9D93-324848FCAE2EQ36439072-FCA6BB88-26DA-49AC-86AE-847326FB5602Q37250189-53F2D082-842F-4241-8479-07AF190A40F5Q38266421-D053E061-4409-45E4-8586-433F971D4777Q38425879-E5778E2A-D47F-4211-887A-9FAF3066069EQ38522574-118E28A9-7F5C-4332-A6C3-88B0D39E686AQ38575714-14E49A41-CB42-4E4A-89DA-6B105D41E808Q38646905-BBD79327-F10B-4034-B755-4981C1EB8AF2Q38829519-A9938E2E-8F7C-4238-BE69-4080C854C37AQ39267105-317C317E-47B6-4441-B7B0-A9E68085A160Q41687426-D589494B-07D2-47A2-85BE-B573176C0617Q48667274-6A250831-ACCE-44B4-8570-14957657CFC8
P2860
Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Comparative in vitro activity ...... Staphylococcus aureus (hVISA).
@en
Comparative in vitro activity ...... Staphylococcus aureus (hVISA).
@nl
type
label
Comparative in vitro activity ...... Staphylococcus aureus (hVISA).
@en
Comparative in vitro activity ...... Staphylococcus aureus (hVISA).
@nl
prefLabel
Comparative in vitro activity ...... Staphylococcus aureus (hVISA).
@en
Comparative in vitro activity ...... Staphylococcus aureus (hVISA).
@nl
P2093
P1476
Comparative in vitro activity ...... Staphylococcus aureus (hVISA).
@en
P2093
Ilona V Grigoryan
Maria Zolotarev
Steven N Leonard
Yong G Szeto
P304
P356
10.1016/J.IJANTIMICAG.2011.02.007
P577
2011-04-14T00:00:00Z